Novartis is paying Sironax $125 million to take up its option on a brain delivery platform, gaining control of technology for getting large molecules to targets in the central nervous system.
Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula
Novartis is paying Sironax $125 million to take up its option on a brain delivery platform, gaining control of technology for getting large molecules to targets in the central nervous system.